All In Biotech

Drug Trial Radar · NCT05668013

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

A Phase 2b, Randomized, Double-Blind Long-Term Extension Study to Evaluate Pharmacokinetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Treatment Phase of the Dose-Ranging Study (RELIEVE UCCD LTE)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 247 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

247

Actual

Start

Jan 11, 2023

Primary completion

Jan 5, 2026

Study completion Jan 31, 2027

Sponsor

Sponsor type
Industry
Collaborators
Sanofi
First posted
Dec 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 4 weeks (Q4W) in adult participants with inflammatory bowel disease (IBD). Secondary objectives of the study are to: * evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD * evaluate the safety and tolerability of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD * evaluate the immunogenicity of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD The total duration for a participant in the double-blind period only is 66 weeks; and for a participant in the open-label extension (OLE) period, up to an additional 268 weeks.

Conditions

  • Crohn Disease
  • Colitis, Ulcerative

Interventions

  • TEV-48574 Dose Regimen ADrug

    Subcutaneous (sc) administration using a commercial sc infusion system

  • TEV-48574 Dose Regiment BDrug

    Subcutaneous (sc) administration using a commercial sc infusion system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with moderate to severe ulcerative colitis (UC) who show clinical remission as defined by the Mayo scoreTime frame: Week 44
  2. Number of participants with moderate to severe Crohn's disease (CD) who show an endoscopic response as defined by the Endoscopic Score for Crohn's DiseaseTime frame: Week 44

Locations

93 sites in 16 countries. Site status is shown where the registry gives one.

  • Clinical Applications Laboratories Inc

    San Diego, California

  • I.H.S. Health

    Kissimmee, Florida

  • Endoscopic Research, Inc.

    Orlando, Florida

  • Gastro Florida

    Pinellas Park, Florida

  • Illinois Gastroenterology Group d/b/a GI Alliance - Gurnee

    Gurnee, Illinois

  • Gastroenterology Health Partners, PLLC

    New Albany, Indiana

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Gastroenterology Health Partners, PLLC - Central Louisville

    Louisville, Kentucky

  • BVL Clinical Research

    Liberty, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Vector Clinical Trials

    Las Vegas, Nevada

  • Dayton Gastroenterology, LLC - Beavercreek

    Beavercreek, Ohio

  • Texas Digestive Specialists

    Harlingen, Texas

  • Gastro Health & Nutrition - Katy

    Katy, Texas

  • Gastroenterology Research of San Antonio LLC

    San Antonio, Texas

  • Texas Digestive Disease Consultants, PLLC. dba GI Alliance - Southlake

    Southlake, Texas

  • Tyler Research Institute, LLC

    Tyler, Texas

  • Care Access

    Salt Lake City, Utah

  • Medical University Vienna

    Vienna, Austria

  • Multiprofile Hospital For Active Treatment St. Ivan Rilski Gorna Oriahovitsa EOOD

    Gorna Oryahovitsa, Bulgaria

  • 20th Diagnostic Consultancy Center, Sofia

    Sofia, Bulgaria

  • University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic, Sofia

    Sofia, Bulgaria

  • Military Hospital Brno

    Brno, Czechia

  • GASTRO JeKa s.r.o.

    Klatovy, Czechia

  • Hospital Slany

    Slaný, Czechia

  • Israeli - Georgian Medical Research Clinic Healthycore LLC

    Tbilisi, Georgia

  • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC

    Tbilisi, Georgia

  • University Hospital Schleswig-Holstein

    Kiel, Germany

  • University Hospital Tuebingen

    Tübingen, Germany

  • University Hospital Ulm

    Ulm, Germany

  • Group Practice Jakobeit

    Wipperfürth, Germany

  • Semmelweis University, Department of Internal Medicine and Hematology

    Budapest, Hungary

  • Clinexpert Ltd. Budapest

    Budapest, Hungary

  • Javorszky Odon Hospital Vac

    Vác, Hungary

  • HaEmek Medical Center

    Afula, Israel

  • Soroka University Medical Center

    Beersheba, Israel

  • Hospital San Raffaele, IRCCS

    Milan, Italy

  • ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Polo University

    Milan, Italy

  • Clinical Institute Humanitas, IRCCS

    Rozzano, Italy

  • Kokikai Tsujinaka Hospital Kashiwanoha, Department of Gastroenterology

    Kashiwa, Japan

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.